Date:8/25/2009

ch actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we, together with our collaborative partners, may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circums
'/>"/>

SOURCE Cardiome Pharma Corp. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
2. Cardiome to Hold Conference Call
3. Cardiome Announces Management Transition
4. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
5. Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
6. Cardiome Reports First Quarter Results
7. Cardiome to Hold Conference Call
8. CardioCareLive.com, First Ever Online Cardiometabolic Conference, Revolutionizes Continuing Medical Education for Cardiovascular Healthcare Professionals
9. Cardiome Reports 2008 Results
10. CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today
11. Noninvasive Medical Technologies to Exhibit at CardioCareLive - A Premier Cardiometabolic Conference